Breaking

North Shore Makes Final Option Payment And Completes Earn-In For West Bear Property
Quimbaya Gold Expands Strategic Land Position at Tahami Project
Lahontan Closes Strategic York Claims Purchase at Santa Fe
Gold and Crypto: Redefining the Future of Finance
CleanAI: The Next Frontier in Climate Tech Investment
Sun Summit Minerals to Present at the 51st Annual New Orleans Investment Conference, November 2-5, 2025
Quimbaya Gold Announces C$10 Million Bought Deal Financing
Queensland Uranium and Rare Earth Acquisition Completed

Business
World News
Investing
Stocks
Search for:

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Quimbaya Gold Expands Strategic Land Position at Tahami Project

October 24, 2025

North Shore Makes Final Option Payment And Completes Earn-In For West Bear Property

October 24, 2025

Lahontan Closes Strategic York Claims Purchase at Santa Fe

October 24, 2025

Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (526)
- Investing (2,177)
- Stocks (647)
- World News (1,658)

Disclaimer: greenety.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2025 greenety.com | All Rights Reserved

Top

Business
World News
Investing
Stocks

Type above and press Enter to search. Press Esc to cancel.